Skip to content Skip to sidebar Skip to footer

Newsletter

Healthcare Stocks

Merck & Co (NYSE:MRK): Its a top 5 healthcare company, but needs to figure out its post-Keytruda future

Merck & Co (NYSE:MRK) is one of the world's most prominent healthcare companies. The healthcare industry is perceived by many investors to be one of the best industries to invest in because it is resilient to adverse economic conditions, but also offers substantial growth opportunities as new innovations can quickly take off given the impact…

ByNick SundichAugust 15, 2025

Telix SEC Subpoena Explained: Why the Stock Plunged 31%

What Investors Need to Know About the Telix SEC Subpoena What happens when a fast-growing biotech lands a major U.S. listing, then suddenly finds itself in the SEC’s crosshairs? That’s the question Telix Pharmaceuticals (ASX:TLX) investors are now asking after the company disclosed it had received a subpoena from the U.S. Securities and Exchange Commission.…

ByCharlie YouldenAugust 8, 2025

ResMed (ASX:RMD): Investors who bought the dip would be satisfied, but is there any growth left in this one?

ResMed (ASX:RMD) is one of the few ASX healthcare stocks that has successfully made it in the USA. And while Trump's tariffs have caused headaches for many healthcare stocks, ResMed might even be a beneficiary of them. Yes, there was a temporary dip in the share price, but shares are up more than 20% in…

ByNick SundichAugust 5, 2025

As ASX Reporting Season for FY25 Looms: Here’s An Investors Ultimate Guide

ASX Reporting Season is almost upon us once again. It is the most important time of the year for investors, a time many reconsider if their thesis still holds, many choose to buy into a stock or sell, some will receive dividends (either expectedly or unexpectedly) whilst others will be disappointed. While you may not…

ByNick SundichJuly 23, 2025

Is it possible for an investor to ‘time the market’ or is it just a myth?

Is it possible at all to time the market? Some will tell you it is possible, but they were probably just lucky and/or were not even trying to. Others will tell you it is not possible, but they are most likely trying to find an excuse to blame poor short-term performance. Let's take a serious look…

ByNick SundichJuly 21, 2025

How Trump’s Proposed 200% Tariffs Could Hit CSL (ASX:CSL) and Other Aussie Biotechs

Donald Trump's Tariffs Could Hit CSL and other Aussie Biotechs...it is a reality that is sinking in for many investors. One of the US President's latest proposals — a 200% tariff on imported pharmaceuticals — has sent shockwaves through the healthcare sector. And yes, that includes close allies like Australia. For investors in CSL (ASX: CSL)…

ByUjjwal MaheshwariJuly 17, 2025

Atomo Diagnostics investors are excited about their fair share from Lumos Diagnostics’ A$487m distribution deal

Wednesday 16 July 2025 was a great day for Atomo Diagnostics (ASX:AT1) investors as shares climbed up to 56% higher and closed 25% above the previous day's closing price. The catalyst was an A$487m deal signed by Lumos Diagnostics, one of Atomo's key business partners and investors believe the company will carve out some of…

ByNick SundichJuly 17, 2025

Trump’s Trade Threats: What ASX Investors Should Watch Across Sectors

As trade tensions flare under Donald Trump's leadership, the global economic landscape is once again facing turmoil. This time, Trump’s rhetoric has brought forward threats of higher tariffs on various imports, including pharmaceutical products and copper. While these threats may seem distant to Australian investors, the potential impacts are significant and should not be underestimated.…

ByUjjwal MaheshwariJuly 16, 2025

Here Are 4 Dogs of the ASX that will Bounce Back With a Vengeance in FY26, and 4 That Won’t

Have you ever heard the term Dogs of the ASX? It can either allude to the worst stocks in the ASX generally, or perhaps the investment strategy of buying these worst performing shares at the start of a new year (either a calendar or financial year), thinking they will rebound. Many will be considering this strategy,…

ByNick SundichJuly 14, 2025

SDI (ASX:SDI): Will slow and steady win the race?

If you're looking for a stock that'll make you a fortune, SDI (ASX:SDI) might not be the best one for you. But if you just want a stock that has little downside risk, it might be more appropriate - but we can only say might. Given the record of dental stocks on the ASX, you might…

ByNick SundichJuly 11, 2025

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Merck & Co (NYSE:MRK): Its a top 5 healthcare company, but needs to figure out its post-Keytruda future

Telix SEC Subpoena Explained: Why the Stock Plunged 31%

ResMed (ASX:RMD): Investors who bought the dip would be satisfied, but is there any growth left in this one?

As ASX Reporting Season for FY25 Looms: Here’s An Investors Ultimate Guide

Is it possible for an investor to ‘time the market’ or is it just a myth?

How Trump’s Proposed 200% Tariffs Could Hit CSL (ASX:CSL) and Other Aussie Biotechs

Atomo Diagnostics investors are excited about their fair share from Lumos Diagnostics’ A$487m distribution deal

Trump’s Trade Threats: What ASX Investors Should Watch Across Sectors

Here Are 4 Dogs of the ASX that will Bounce Back With a Vengeance in FY26, and 4 That Won’t

SDI (ASX:SDI): Will slow and steady win the race?

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Stocks in Spotlight

Add Your Heading Text Here